Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies ; volume:24 ; number:1 ; day:8 ; month:10 ; year:2024 ; pages:1-12 ; date:12.2024
BMC neurology ; 24, Heft 1 (8.10.2024), 1-12, 12.2024
- Urheber
-
Zivadinov, Robert
Keenan, Alexander J.
Le, Hoa H.
Ait-Tihyaty, Maria
Gandhi, Kavita
Zierhut, Matthew L.
Salvo-Halloran, Elizabeth M.
Ramirez, Abril Oliva
Vuong, Vivian
Singh, Sumeet
Hutton, Brian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-024-03888-6
- URN
-
urn:nbn:de:101:1-2412252100454.029995240695
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zivadinov, Robert
- Keenan, Alexander J.
- Le, Hoa H.
- Ait-Tihyaty, Maria
- Gandhi, Kavita
- Zierhut, Matthew L.
- Salvo-Halloran, Elizabeth M.
- Ramirez, Abril Oliva
- Vuong, Vivian
- Singh, Sumeet
- Hutton, Brian
- SpringerLink (Online service)
Ähnliche Objekte (12)
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010